NASDAQ: ABVXAbivax Sa Stock
$99.15-1.00 (-1%)
Updated Jun 18, 2026
ABVX Price
$99.15
Fair Value Price
$8.09
Market Cap
$7.83B
52 Week Low
$5.69
52 Week High
$148.83
P/E
-18.77x
P/B
15.49x
P/S
1,554.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.79M
Earnings
-$381.84M
Gross Margin
100%
Operating Margin
-4,341.95%
Profit Margin
-6,752%
Debt to Equity
0.27
Operating Cash Flow
-$205M
Beta
1.6
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABVX Overview
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABVX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ABVX
Ranked#119 of 465
Ranked#119 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important ABVX news, forecast changes, insider trades & much more!
ABVX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABVX ($99.15) is overvalued by 1,125.35% relative to our estimate of its Fair Value price of $8.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABVX ($99.15) is not significantly undervalued (1,125.35%) relative to our estimate of its Fair Value price of $8.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABVX due diligence checks available for Premium users.
Valuation
ABVX fair value
Fair Value of ABVX stock based on Discounted Cash Flow (DCF)
Price
$99.15
Fair Value
$8.09
Overvalued by
1,125.35%
ABVX ($99.15) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABVX ($99.15) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABVX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-18.77x
Industry
15.77x
Market
9.47x
ABVX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.49x
Industry
4.95x
ABVX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABVX's financial health
Profit margin
Revenue
$1.5M
Net Income
-$55.7M
Profit Margin
-3,606.2%
ABVX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABVX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$628.9M
Liabilities
$135.1M
Debt to equity
0.27
ABVX's short-term assets ($603.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABVX's short-term assets ($603.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$58.1M
Investing
$569.0k
Financing
$83.9k
ABVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABVX vs Biotech Stocks
Abivax Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.